<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184492</url>
  </required_header>
  <id_info>
    <org_study_id>GP-40081-P4-11</org_study_id>
    <nct_id>NCT04184492</nct_id>
  </id_info>
  <brief_title>A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects</brief_title>
  <official_title>A Randomized Double Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of GP-40081 (LLC &quot;GEROPHARM&quot;, Russia) Versus NovoMix® 30 Penfill® (Novo Nordisk) in Healthy Subjects Using the Euglycemic Clamp Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and pharmacodynamics study of 2 formulations of biphasic insulin aspart 30
      (GP-40081 GEROPHARM vers. NovoMix® 30 Penfill® Novo Nordisk)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double blinded two-way crossover single-dose pharmacokinetics and
      pharmacodynamics study of GP-40081 (LLC &quot;GEROPHARM&quot;, Russia) versus NovoMix® 30 Penfill®
      (Novo Nordisk) in normal healthy subjects using the euglycemic clamp technique
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This study was blinded for Sponsor, investigators and analytical laboratory</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>-60, -30, 0 minutes (pre-dose) and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 210, 240, 270, 300, 360, 420, 480, 600, 720, 960, 1200 and 1440 minutes post-dose</time_frame>
    <description>Pharmacokinetics of insulin aspart by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-60, -30, 0 minutes (pre-dose) and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 210, 240, 270, 300, 360, 420, 480, 600, 720, 960, 1200 and 1440 minutes post-dose</time_frame>
    <description>Pharmacokinetics of insulin aspart by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Clamp Study</condition>
  <arm_group>
    <arm_group_label>GP-40081</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoMix® 30 Penfill®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP-40081</intervention_name>
    <description>biphasic insulin aspart 30 in doses 0.4 IU/kg</description>
    <arm_group_label>GP-40081</arm_group_label>
    <other_name>biphasic insulin aspart 30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NovoMix® 30 Penfill®</intervention_name>
    <description>biphasic insulin aspart 30 in doses 0.4 IU/kg</description>
    <arm_group_label>NovoMix® 30 Penfill®</arm_group_label>
    <other_name>biphasic insulin aspart 30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent.

          2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical,
             laboratory, and instrumental examination methods.

          3. Age of 18-45 (both incl.).

          4. Body mass index equal to 18.5-30.0 kg/m2, body weight equal to 60.0-100.0 kg (both
             incl.).

          5. Volunteers' consent to all restrictions imposed during the study, including adequate
             methods of contraception.

          6. Russian citizenship.

        Exclusion Criteria:

          1. Weighed allergic anamnesis.

          2. Increased sensitivity in the history of heparin, insulin or any of the excipients of
             the study drugs.

          3. Any acute and chronic diseases (for 4 weeks before screening) incl.:

               1. of the cardiovascular system, bronchopulmonary, neuroendocrine systems, as well
                  as diseases of the gastrointestinal tract, liver, kidneys, blood.

               2. positive tests: hepatitis B (Ag), hepatitis C (Ab), HIV (Ab), syphilis (Ab).

          4. Deviations in basic vital signs: heart rate (60-89), systolic blood pressure (90-139
             mm Hg), the diastolic blood pressure (60-89 mm Hg), respiratory rate (12-20), body
             temperature (35.7-37.2 C).

          5. Abnormalities of the ECG from the norms.

          6. Episodes of hypoglycemia in the anamnesis; the presence in the family history of cases
             of a verified diagnosis of diabetes mellitus in the immediate family.

          7. Fasting plasma glucose&gt; 6.1 mmol / L.

          8. HbA1C&gt; 6% (screening).

          9. Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after
             loading with glucose).

         10. Deep vein thrombosis of lower extremities in a history of life or in a family history.

         11. Any diet (vegetarian, etc.), extreme physical exercise, night shift work.

         12. Subjects who have taken any drugs known effects on hemodynamics or to induce or
             inhibit hepatic drug metabolism within 2 months prior to screening.

         13. Taking medications, phytopreparations, biologically active supplements less than 14
             days before screening.

         14. History of significant drugs abuse conditions for 3 years prior to screening.

         15. Significant blood loss (450 mL or more) less than 3 months before the screening.

         16. Recovery after surgery process; scheduled surgery.

         17. Mental, physical and other reasons that do not allow to adequately assess their
             behavior and properly fulfill the conditions of the research protocol, including
             psychiatric disorders.

         18. A positive test for the content of drugs in the urine (screening).

         19. Positive test for alcohol content in the exhaled air.

         20. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5
             liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information
             about alcoholism.

         21. Nicotine dependence (use of tobacco less than 6 months before the start of screening).

         22. Participation in a clinical trial of any medications less than 3 months or 5
             half-lives before the IP administration.

         23. Any conditions that make it difficult, according to the informed opinion of the
             investigating physician, that volunteer participation in studies.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Endocrinology Research Centre</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Biphasic Insulin Aspart</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

